---
document_datetime: 2025-10-14 14:34:09
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/arikayce-liposomal-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: arikayce-liposomal-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2468489
conversion_datetime: 2025-12-29 22:00:40.495074
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ARIKAYCE liposomal

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 18/09/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000284843   | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add (Pharyngeal swelling, Nasal dryness, Epistaxis, Rhinorrhoea, Sneezing, Nasal Congestion, Dysphagia, Glossitis, Glossodynia, Salivary hypersecretion, Stomatitis, Abdominal pain, Abdominal pain upper, Abdominal discomfort, Abdominal distension) to the list of adverse drug reactions (ADRs) with frequency (Not known) based on post-marketing data. The Package Leaflet is updated accordingly.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|